| Literature DB >> 35215430 |
Glyn Howatson1,2, Gemma C Snaith1, Rachel Kimble3, Gavin Cowper1, Karen M Keane1,4.
Abstract
BACKGROUND: Food high in (poly)phenolic compounds, such as anthocyanins, have the potential to improve exercise recovery and exercise performance. Haskap berries are rich in anthocyanins, but no research has examined the potential to improve human performance. The aim of this study was to determine the influence of Haskap berry on parameters of endurance running performance.Entities:
Keywords: (poly)phenols; anthocyanins; human performance; recovery; time to exhaustion; time trial
Mesh:
Substances:
Year: 2022 PMID: 35215430 PMCID: PMC8877138 DOI: 10.3390/nu14040780
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Schematic representation of the study design on Trial 1 and Trial 2.
Participant characteristics for the Haskap and Control groups.
| Age (years) | Stature (cm) | Mass (kg) | 5 km TT (s) | Training Volume (min/week) | |
|---|---|---|---|---|---|
|
| 30 ± 8 | 176.5 ± 5.3 | 75.0 ± 10.9 | 1377 ± 192 | 281 ± 142 |
|
| 35 ± 6 | 179.8 ± 8.6 | 80.4 ± 10.0 | 1299 ± 141 | 245 ± 156 |
Data from the submaximal test for lactate threshold (LT) parameters before and after the intervention of Haskap or placebo control.
| ANCOVA Adjusted for Baseline | ||||||
|---|---|---|---|---|---|---|
| Control | Haskap | Difference (95% CI) | F | Effect Size | ||
|
| ||||||
| Pre | 11.7 ±1.9 | 12.1 ± 1.8 | 0.26 (−0.68–0.22) | 1.062 | 0.312 | 0.038 |
| Post | 11.7 ± 1.9 | 12.4 ± 1.7 | ||||
|
| ||||||
| Pre | 158 ± 10 | 151 ± 10 | 3.3 (0.67–5.98) | 6.639 | 0.016 | 0.197 |
| Post | 159 ± 10 | 149 ± 9 | ||||
|
| ||||||
| Pre | 11.6 ± 2.1 | 12.1 ± 2.3 | 0.03 (−0.94–0.88) | 0.005 | 0.944 | <0.001 |
| Post | 11.4 ± 2.1 | 11.8 ± 2.0 | ||||
|
| ||||||
| Pre | 39.6 ± 5.7 | 40.7 ± 5.0 | 2.2 (0.67–3.69) | 8.799 | 0.006 | 0.246 |
| Post | 40.4 ± 5.6 | 39.3 ± 5.3 | ||||
|
| ||||||
| Pre | 2946 ± 468 | 3248 ± 413 | 131 (16.6–246) | 5.517 | 0.026 | 0.170 |
| Post | 2998 ± 404 | 3139 ± 440 | ||||
Data are presented as mean ± SD; n = 30 (15 in each group). * denotes significant differences between groups.
Data from the submaximal test for lactate turnpoint (LTP) parameters before and after the intervention of Haskap or placebo control.
| ANCOVA Adjusted for Baseline | ||||||
|---|---|---|---|---|---|---|
| Control | Haskap | Difference (95% CI) | F | Effect Size | ||
|
| ||||||
| Pre | 13.3 ± 1.7 | 14.1 ± 1.6 | 0.177 (−0.20–0.56) | 0.925 | 0.345 | 0.033 |
| Post | 13.5 ±1.7 | 14.0 ± 1.7 | ||||
|
| ||||||
| Pre | 171 ± 8 | 169 ± 7 | 5.3 (2.82–7.69) | 19.534 | <0.001 | 0.420 |
| Post | 172 ± 8 | 165 ± 6 | ||||
|
| ||||||
| Pre | 14.9 ± 1.5 | 14.7 ± 2.2 | 0.14 (−0.49–0.76) | 0.201 | 0.657 | 0.007 |
| Post | 15.0 ± 1.2 | 14.7 ± 2.1 | ||||
|
| ||||||
| Pre | 44.6 ± 6.1 | 46.0 ± 5.0 | 0.6 (−0.84–2.11) | 0.786 | 0.383 | 0.028 |
| Post | 45.2 ± 6.3 | 45.8 ± 5.1 | ||||
|
| ||||||
| Pre | 3328 ± 522 | 3676 ± 403 | 0.45 (−112.10–113.01) | <0.001 | 0.993 | <0.001 |
| Post | 3358 ± 478 | 3656 ± 378 | ||||
Data are presented as mean ± SD; n = 30 (15 in each group); * denote significant differences between groups.
Data from the O2peak test before and after the intervention of Haskap.
| ANCOVA Adjusted for Baseline | ||||||
|---|---|---|---|---|---|---|
| Control | Haskap | Difference (95% CI) | F | Effect Size | ||
|
| ||||||
| Pre | 481.6 ± 65.5 | 466.5 ± 87.3 | 20.0 (2.0–38.1) | 5.174 | 0.031 | 0.161 |
| Post | 484.5 ± 69.8 | 488.5 ± 98.3 | ||||
|
| ||||||
| Pre | 188 ± 11 | 185 ± 10 | 1.9 (−1.1–4.8) | 1.683 | 0.206 | 0.058 |
| Post | 189 ± 10 | 184 ± 11 | ||||
|
| ||||||
| Pre | 18.7 ± 1.2 | 18.7 ± 1.3 | 0.35 (−0.12–0.81) | 2.348 | 0.137 | 0.080 |
| Post | 18.9 ± 0.9 | 18.5 ± 1.4 | ||||
|
| ||||||
| Pre | 7.68 ± 1.98 | 7.10 ± 1.86 | 0.22 (−1.43–0.98) | 0.144 | 0.707 | 0.005 |
| Post | 7.42 ± 2.01 | 7.26 ± 1.99 | ||||
| Pre | 53.2 ± 6.6 | 52.2 ± 4.8 | 0.7 (−2.11–0.69) | 1.096 | 0.304 | 0.039 |
| Post | 53.6 ± 6.7 | 53.4 ± 4.8 | ||||
|
| ||||||
| Pre | 3956 ± 493 | 4175 ± 439 | 0.45 (−112.10–113.01) | 2.317 | 0.140 | 0.79 |
| Post | 3968 ± 467 | 4265 ± 463 | ||||
Data are presented as mean ± SD; n = 30 (15 in each group); * denote significant differences between groups.
Figure 2The change in time to exhaustion (TTE) during the O2peak test in the placebo control (CON) and Haskap (HB) groups. Data are presented as mean ± SD; n = 30 (15 in each group); * denote significant differences between groups.
Data from the 5 km time trial (TT) before and after the intervention of Haskap or placebo control.
| ANCOVA Adjusted for Baseline | ||||||
|---|---|---|---|---|---|---|
| Control | Haskap | Difference (95% CI) | F | Effect Size | ||
|
| ||||||
| Pre | 13.33 ± 2.06 | 14.01 ± 1.62 | 0.25 (0.12–0.38) | 15.162 | 0.001 | 0.387 |
| Post | 13.27 ± 2.08 | 14.21 ± 1.66 | ||||
|
| ||||||
| Pre | 1377 ± 192 | 1299 ± 141 | 20.9 (4.2–37.7) | 6.662 | 0.016 | 0.217 |
| Post | 1384 ± 193 | 1282 ± 140 | ||||
|
| ||||||
| Pre | 18.2 ± 0.7 | 18.3 ± 1.0 | 0.31 (−0.22–0.84) | 1.402 | 0.248 | 0.055 |
| Post | 18.5 ± 1.0 | 18.3 ± 1.1 | ||||
|
| ||||||
| Pre | 4.95 ± 1.57 | 6.49 ± 1.93 | 0.12 (−0.88–1.12) | 0.062 | 0.805 | 0.003 |
| Post | 5.48 ± 1.71 | 6.27 ± 1.37 | ||||
|
| ||||||
| Pre | 186 ± 10 | 186 ± 14 | 0.3 (−2.6–3.3) | 0.054 | 0.818 | 0.002 |
| Post | 186 ± 10 | 186 ± 13 | ||||
|
| ||||||
| Pre | 177 ± 13 | 178 ± 13 | 0.19 (−0.31–3.34) | 0.015 | 0.905 | 0.001 |
| Post | 175 ± 12 | 176 ± 12 | ||||
Data are presented as mean ± SD; n = 27 (13 in the placebo control and 14 in the Haskap group); * denote significant differences between groups.
Figure 3The change in time to mean speed during the 5 km time trial; TT (Panel A) and the change in 5 km TT performance (Panel B) in the placebo control (CON; n = 13) and Haskap (HB; n = 14) groups. Data are presented as mean ± SD; * denote significant differences between groups.